10. Patients with serious physical diseases, such as cancer;
11. Patients who have a history of allergy to the investigational drug or its ingredients;
12. Participating in other clinical investigators;
13. During the study period, Patients cannot live in the selected center for a long time, which is not conducive to the follow-up;
14. Patients with disability, mobility disability, intellectual disability and other factors that may prevent normal participation in the study and follow-up, and their frailty was assessed by the FRAIL frailty screening scale; Intellectual mental status was assessed by the Mini-Mental State Examination (MMSE).
15. Poor adherence or other reasons considered by the researchers to be unsuitable for the clinical trial.
Clareo Health | Metoprolol in Patients With HFrEF and COPD
